A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2015
Price : $35 *
At a glance
- Drugs Decoglurant (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Roche
- 26 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Oct 2014 Planned End Date changed from 1 Mar 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 20 Oct 2014 Planned primary completion date changed from 1 Mar 2016 to 1 Nov 2015 as reported by ClinicalTrials.gov record.